Read more about the article Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing

Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing

Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats acute respiratory distress syndrome (ARDS)…

Continue ReadingLearn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing
Read more about the article Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19

Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19

Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 TORONTO, Ontario -…

Continue ReadingVasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19